Stay updated on Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Sign up to get notified when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.

Latest updates to the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page
- Check3 days agoChange DetectedNapoli, Italy, 80131 was updated to Naples, Italy, 80131 in the locations listing, a Genetic and Rare Diseases Information Center resource was added, the Hepatocellular carcinoma term was added, and the revision version changed from v3.4.3 to v3.5.0.SummaryDifference0.1%

- Check10 days agoNo Change Detected
- Check18 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. The change does not modify visible study details, eligibility criteria, locations, or outcomes on the page.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 was removed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1, a minor system update with no user-facing content changes. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check61 days agoChange DetectedGlossary visibility controls were added (Show glossary / Hide glossary) and the page revision updated to v3.4.0. Update-related fields were reorganized: Last Update Submitted that Met QC Criteria and Last Update Posted were added, while the previous labels Last Update Submitted that met QC Criteria, Last Update Posted (Estimated), and No FEAR Act Data were removed or adjusted.SummaryDifference0.1%

- Check68 days agoChange DetectedRevision updated from v3.3.3 to v3.3.4 on the page. This appears to be a metadata/version update and does not alter study details, eligibility criteria, or locations.SummaryDifference0.0%

Stay in the know with updates to Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab for High-Risk HCC Post-Hepatic Tx Clinical Trial page.